ArticleThe Journal of neuroscience : the official journal of the Society for Neuroscience2010
Escitalopram enhances the association of serotonin-1A autoreceptors to heteroreceptors in anxiety disorders.
Article in The Journal of neuroscience : the official journal of the Society for Neuroscience, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 56 citations in OpenAlex.
- One-week escitalopram intake alters the excitation-inhibition balance in the healthy female brain.Human brain mapping · 2022Trial
- Effects of Silexan on the serotonin-1A receptor and microstructure of the human brain: a randomized, placebo-controlled, double-blind, cross-over study with molecular and structural neuroimaging.The international journal of neuropsychopharmacology · 2014Trial
- Mapping dynamics in neuronal activation and molecular connectivity with functional PET.Frontiers in neuroscience · 2026Review
- Connecting the dots: approaching a standardized nomenclature for molecular connectivity in positron emission tomography.European journal of nuclear medicine and molecular imaging · 2025Review
- In vivo serotonin 1A receptor distribution in treatment-resistant depression.Translational psychiatry · 2025Article
- Article
- Molecular connectivity studies in neurotransmission: a scoping review.Imaging neuroscience (Cambridge, Mass.) · 2025Article
- SSRI use during acute COVID-19 and risk of long COVID among patients with depression.BMC medicine · 2024Observational
- Serotonergic Neurotransmission in Limbic Regions May Reflect Therapeutic Response of Depressive Patients: A PET Study With 11C-WAY-100635 and 18F-MPPF.The international journal of neuropsychopharmacology · 2023Article
- Increased left dorsolateral prefrontal cortex density following escitalopram intake during relearning: a randomized, placebo-controlled trial in healthy humans.Therapeutic advances in psychopharmacology · 2022Article
- The Impact of Theta-Burst Stimulation on Cortical GABA and Glutamate in Treatment-Resistant Depression: A Surface-Based MRSI Analysis Approach.Frontiers in molecular neuroscience · 2022Article
- From metabolic connectivity to molecular connectivity: application to dopaminergic pathways.European journal of nuclear medicine and molecular imaging · 2020Article
- Molecular connectivity disruptions in males with major depressive disorder.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2019Article
- Making Sense of Connectivity.The international journal of neuropsychopharmacology · 2019Review
- Will imaging individual raphe nuclei in males with major depressive disorder enhance diagnostic sensitivity and specificity?Depression and anxiety · 2018Article
- Altered interregional molecular associations of the serotonin transporter in attention deficit/hyperactivity disorder assessed with PET.Human brain mapping · 2017Article
- Effects of Selective Serotonin Reuptake Inhibitors on Interregional Relation of Serotonin Transporter Availability in Major Depression.Frontiers in human neuroscience · 2017Article
- Prenatal stress, regardless of concurrent escitalopram treatment, alters behavior and amygdala gene expression of adolescent female rats.Neuropharmacology · 2015Article
- Pharmacotherapy of anxiety disorders in German-speaking countries: current status and changes between 1994 and 2011.European archives of psychiatry and clinical neuroscience · 2015Article
- Citalopram protects against cold-restraint stress-induced activation of brain-derived neurotrophic factor and expression of nuclear factor kappa-light-chain-enhancer of activated B cells in rats.Journal of molecular neuroscience : MN · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Selective serotonin reuptake inhibitors (SSRIs) represent one of the most common treatment options in major depression and anxiety disorders. By blocking the serotonin transporter, SSRIs modulate serotonergic neurotransmission as well as the function of autoreceptors and heteroreceptors. However, treatment-induced changes on a network level primarily remain unknown. Thus, we evaluated the association between serotonin-1A (5-HT1A) autoreceptors and heteroreceptors before and after SSRIs. Twenty-one patients with anxiety disorders underwent positron emission tomography using [carbonyl-11C]WAY-100635 before and after 12 weeks of escitalopram treatment; 15 of them completed the study protocol. Additionally, 36 drug-naive healthy controls were measured once. The 5-HT1A receptor binding potential (BPND) was quantified for the dorsal raphe nucleus (DRN) using a region-of-interest approach and for the entire brain by calculating parametric maps. Voxel-wise linear regression was applied between DRN autoreceptor and whole-brain heteroreceptor 5-HT1A BPND. Consistent with previous observations, healthy subjects showed widespread positive correlations of 5-HT1A BPND between autoreceptors and heteroreceptors. Comparing patients before versus after escitalopram treatment revealed enhanced associations of autoreceptor-to-heteroreceptor 5-HT1A BPND within the amygdala and hippocampus (R2=0.21-0.28 vs 0.49-0.81; p<0.05-0.001). In contrast, no significant SSRI-induced changes were found for correlations of heteroreceptor-to-heteroreceptor 5-HT1A BPND between several limbic regions. This interregional approach suggests a treatment-induced reinforcement of the association of 5-HT1A binding between autoreceptors and heteroreceptors specifically in areas involved in anxiety disorders. These findings provide complementary information about treatment effects on a network level and confirm the central role of the DRN as a prime regulatory area.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.